Cutting-Edge Pharmacological Treatment for Obesity

We create well-being through innovative and personalized therapeutics solutions. Our commitment is to improve the quality of life of our patients

About us

Eolo Pharma is a company dedicated to improving the health and well-being of individuals. Our high-quality products are designed to enhance energy and vitality, providing innovative solutions for healthcare.



Our NCE library is composed of 60 novel molecules. Within our pipeline we highlight MVD1, our lead compound for Obesity and its comorbidities.

Drug Candidate
Discovery & chracterization
Phase I
Phase II
Phase III
Obesity T2 Diabetes NASH Hypertension
Oral thermogenic NCE
MVD 1 analog
ALS Alzheimer's
NF-kB inhibitor & other


Our NCE library is consists of a unique collection of small molecules. Within our pipeline we highlight MVD1, our lead compound for Obesity and its comorbidities.

Obesity and its comorbidities are becoming pandemic and a prime driver of healthcare burden worldwide. While obesity can be considered an independent disease, it is the primary mediator of metabolic syndrome, the principal risk factor for Type II diabetes and cardiovascular diseases.

Dive into

our world

High-quality products are designed to enhance energy and vitality

Discover the essential elements of our brand platform.

Our purpose  & vision

Get to know about our latest research and developments.

NCE library

Stay up to date with Eolo’s latest events 

Read our latest news

For more information or work applications please reach out to us

Get in touch

Research at Eolo

Discover our collection of peer-reviewed publications, unveiling groundbreaking research in various fields. Engage with our insightful works that bridge science and innovation, offering valuable insights into obesity, ALS, and tissue transplantation. Join us in exploring the forefront of knowledge and unlocking new possibilities in healthcare.

A Nitroalkene Benzoic Acid Derivative Targets Reactive Microglia and Prolongs Survival in an Inherited Model of ALS via NF-κB Inhibition.

A novel nitroalkene vitamin E analogue inhibits the NLRP3 inflammasome and protects against inflammation and glucose intolerance triggered by obesity

Electrophilic nitroalkene-tocopherol derivatives: synthesis, physicochemical characterization and evaluation of anti-inflammatory signaling responses

Partners & supporters